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Objectives: Artemisinin combination based therapy (ACT) was started in Ghana in 
2002 as a result of failure of monotherapy in the treatment of falciparum malaria. 
The decision to change was in line with recommendations from the World Health 
Organisation. ArtesunateAmodiaquine (A-Q) is the preferred combination drug of 
choice for the treatment of uncomplicated malaria and Artemether-Lumefantrine 
(A-L) is an alternative first line option. This study evaluates the cost-effectiveness 
of A-Q compared with A-L among under-five year olds in Ghana. MethOds: In 
this study a decision analytic model using a decision tree was developed to assess 
the cost-effectiveness of the two treatments. Cost of illness and cost of medication 
(Coartem paediatric and Camoquine plus) were determined using figures from the 
National Health Insurance Scheme (NHIS) Ghana and from wholesalers respectively. 
Transportation cost was estimated using exit interviews. With the help of rand-
omized controlled trials we estimated malaria cases averted (using clinical failure 
rates) over a 28 day period post treatment with each drug. Costs were discounted 
by 3% over a five year period but malaria cases averted 28 days after treatment 
was not discounted. Incremental costs per uncomplicated malaria case averted 
was then determined. Results: The cost of illness per episode of uncomplicated 
malaria was 7.50 Ghana cedis (bundled NHIS cost) and transportation cost was 3.00 
Ghana cedis. The incremental cost effectiveness ratio of artesunate-amodiaquine 
compared with artemether-lumefantrine was 16 Ghana cedis per uncomplicated 
malaria case averted. cOnclusiOns: This economic evaluation showed that in the 
Ghanaian setting, treating uncomplicated malaria in under-five year old children 
with artesunate-amodiaquine was more cost-effective compared with artemether-
lumefantrine.
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Objectives: Favorable clinical outcomes in HIV-1 infection require optimal 
adherence to multi-drug antiretroviral (ARV) regimens. Single-tablet regimens 
(STRs) simplify treatment compared with multiple-tablet regimens (MTRs) and are 
associated with improved adherence, improved virologic outcomes and reduced 
hospitalizations. To date, models assessing the economic value of STRs have been 
based only on clinical trial evidence from idealized settings with close follow-up. 
Economic models have not yet incorporated real-world evidence comparing adher-
ence and effectiveness between STRs and MTRs. MethOds: A patient-level simu-
lation model was used to compare health and economic outcomes between STRs 
and MTRs in the US. STRs included EVG/COBI/FTC/TDF, EFV/FTC/TDF and RPV/FTC/
TDF. MTRs included a 3rd agent plus 3TC+TDF backbone. Before incorporating real-
world evidence, the model was validated against published economic projections 
based on clinical trial results. Real-world evidence identified via systematic litera-
ture review was then incorporated for differences in adherence, resistance, and 
hospitalization risk between STRs and MTRs. Upcoming generic drug scenarios 
included 25-75% cost reductions and lower average drug costs for MTRs vs. STRs 
by $1,300 to $6,100 per year. All costs were inflated to 2013 USD. Results: After 
incorporating real-world evidence, the virologic suppression rates at 24 weeks 
were 72.7% and 63.2% for STRs and MTRs, respectively. When initiating with STRs 
vs. MTRs, short-term inpatient costs (at 2 years) were reduced by 29% ($7,660 vs. 
$10,819) and an additional 2 life years (20.6 vs. 18.6) were gained. The discounted 
life-time incremental cost-effectiveness ratios ranged from ~$26,000 to $52,000 
per QALY, depending on assumed generic discounts. cOnclusiOns: STRs have 
demonstrated superior clinical and economic outcomes compared to MTRs in 
real-world settings. Incorporating this evidence into a cost-effectiveness model 
illustrated that initiation with STRs is a cost-effective strategy compared with 
initiation with MTRs, due to greater real-world adherence and effectiveness, and 
reduced inpatient costs.
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Objectives: In the United States, chronic hepatitis C (HCV) is responsible for more 
death and disease than HIV/AIDS. It is the most common chronic blood-borne infec-
tion, and remains a major cause of death and illness in the United States. Current 
standard of care treatments for HCV have difficult dosing regimens and are often 
accompanied by undesirable side effects. With a host of new clinically promis-
ing, interferon-free, combo therapies currently in clinical trials it is important to 
assess the cost-effectiveness of the current and future treatment options for chronic 
hepatitis C. The objective of the current study is to assess the cost-effectiveness 
of current, and future, treatment options for treatment naïve genotype 1 chronic 
hepatitis c patients. MethOds: Cost-effectiveness analysis using a Markov model 
of the natural disease progression of HCV infection and impact of treatment. We 
use a simulated 20 year model of a hypothetical cohort of 1000 treatment naïve 
genotype 1 HCV patients to assess the cost-effectiveness of no treatment, boceprevir 
+ pegylated interferon + ribavirin (BOC+P+R), telaprevir + pegylated interferon + 
ribavirin (TVR+P+R), and sofosbuvir + ledipasvir + ribavirin (SOF+LVR+R). Results: 
Over the 20 year time horizon of this cohort no treatment would result in 9.76 QALYs 
and a total discounted cost of $41,434, while BOC+P+R resulted in 11.06 and $132,070, 
TVR+P+R in 11.08 and $132,482, and SOF+LVR+R in 11.90 and $172,384, respectively. 
Our analysis showed that BOC+P+R and TVR+P+R were weakly dominated, while 
SOF+LVR+R was the most cost-effective therapy. cOnclusiOns: The interferon-free 
combo therapy SOF+LVR+R is the most cost-effective treatment option, with an ICER 
of $61,291 when compared to no treatment. These results have important economic, 
and policy implications for the treatment of chronic hepatitis C.
Objectives: The purpose of this cost-effectiveness model is to compare the cost-
effectiveness of metronidazole, oral vancomycin, fidaxomicin, and fecal transplants 
for CDI. MethOds: This is a cost-effectiveness model from the societal perspective 
using probabilities, cost, and utility parameters from scientific literature. A deci-
sion tree model for mild/moderate CDI compares metronidazole, oral vancomycin, 
fidaxomicin, and fecal transplant. A decision tree for severe CDI compares oral 
vancomycin, fidaxomicin, and fecal transplant. Both decision trees capture up to two 
recurrences and/or the necessity of a colectomy. Both models account for short-term 
and long-term costs of CDI. One-way sensitivity and threshold sensitivity analy-
sis were used to assess the robustness of the data. Results: For mild-moderate 
CDI, fecal transplant is a dominant treatment option, as it reduces costs to $13,537 
and increases effect to 11.85 QALYs. The best alternative to fecal transplants in 
mild-moderate disease is fidaxomicin if WTP/QALY > $0. For severe disease, fecal 
transplant is still a dominant treatment option, as it reduces costs to $13,537 and 
increases effect to 11.84 QALYs. The best alternative to fecal transplants in severe 
CDI is oral vancomycin at all WTP/QALY. For mild-moderate disease indicated that 
fecal transplants are favored to fidaxomicin as long as the cost of fecal transplants 
< $4,515, fecal transplant cure rate > 0.883, fecal transplant recurrence rate < 0.185, 
fidaxomicin cure rate < 0.955, and fidaxomicin recurrence rate > 0.02. For severe 
disease indicated that fecal transplants are favored to oral vancomycin as long as 
the cost of fecal transplants < $4,860, fecal transplant cure rate > 0.79, and the fecal 
transplant recurrence rate < 0.36. cOnclusiOns: In both the treatment of mild/
moderate and severe CDI, it is cost-effective to use fecal transplants as standard 
protocol rather than the last resort.
PIN51
Cost-EffECtIvENEss of ErtaPENEM vErsus CEftrIaxoNE IN trEatINg 
urINary traCt INfECtIoNs IN ColoMbIa
Xie Y.1, Lemos E.2, Restrepo M.2, Ruiz J.2, Lozano F.2
1Merck & Co., Whitehouse Station, NJ, USA, 2MSD Colombia, Bogota, Colombia
Objectives: To compare Ertapenem with ceftriaxone for the treatment of uri-
nary tract infections (UTI) in Colombia health care setting, with respect to cost 
and outcomes taking into account development of anti-microbial resistance 
(AMR). MethOds: A previously published decision tree model was adapted to 
estimate cost-effectiveness of Ertapenem vs. Ceftriaxone in the treatment of UTI. 
Clinical efficacy, adverse events and medical resource use were derived from lit-
erature. AMR to Ertapenem and ceftriaxone was calculated as weighted average 
based on the % distribution of different pathogens in UTI in Colombia and the 
sensitivity of Ertapenem and Ceftriaxone to each pathogen from Colombia SMART 
data. The resistance-adjusted effectiveness is then computed based on the effi-
cacy from clinical trial and local AMR data, Model outcomes included resistance, 
clinical success, deaths, life years, direct costs, and costs per successfully treated 
patient. Results: The overall AMR of Ertapenem vs. Ceftriaxone for UTI is 7% 
vs. 30%. The resistance-adjusted effectiveness is 83% vs. 64% for Ertapenem vs. 
Ceftriaxone. Daily drug costs for Ertapenem vs. Ceftriaxone are 133,550 vs. 8,550 
Colombian Pesos. Total costs (including drug costs, hospitalization, cost of 2nd-line 
treatment & cost of AEs) are 446,871 vs. 188,268 Pesos. During the first hospitaliza-
tion period, Ertapenem is associated with a 18.8% higher treatment success rate, 
and 178,377 Pesos more in total cost when compared with Ceftriaxone. The incre-
mental cost per successfully treated patient (ICER) is 9,488 Pesos ($4.87 USD) for 
Ertapenem vs. Ceftriaxone. cOnclusiOns: Accounting for local anti-microbial 
resistance, Ertapenem is more effective as well cost-effective vs. Ceftriaxone for 
the treatment of urinary tract infections in Colombia.
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Objectives: Dolutegravir is a new FDA-approved (August 2013) antiretroviral medi-
cation in the integrase inhibitor class which could be a possible first-line agent for 
treatment of antiretroviral naïve HIV infected adults. A phase III trial (SPRING-2) 
compared clinical efficacy of dolutegravir versus raltegravir, a currently recom-
mended first-line agent, and demonstrated non-inferior viral response rates at 96 
weeks for dolutegravir (81%) when compared to raltegravir (76%). This study aims to 
estimate the costs and effectiveness of dolutegravir and raltegravir and to determine 
the cost-effectiveness of dolutegravir versus raltegravir. MethOds: A decision anal-
ysis model was constructed to determine the cost-effectiveness of treatment with 
dolutegravir versus treatment with raltegravir as a first-line agent from the perspec-
tive of the provider. First-line efficacy data was derived from the previously-men-
tioned published phase-III trial (SPRING-2). Drug costs were estimated using average 
whole sale price and data were obtained using the Red Book. Costs associated with 
second-line treatment as well as adverse effect treatment were also derived from 
the Red Book. The model was run over a period of 192 weeks using TreeAge Pro 
2013. Results: The estimated costs for the dolutegravir arm and raltegravir arm 
at 192 weeks were $100,750.28 and $96,622.17, respectively. The incremental cost-
effectiveness ratio for dolutegravir versus raltegravir was estimated to be $412,811 
per 1% increase in virological success. Sensitivity analysis performed on the cost 
parameters confirmed the primary cost effectiveness results. cOnclusiOns: The 
analysis provided cost-effectiveness findings of dolutegravir versus raltegravir for 
HIV-infected treatment naïve patients and showed favorable cost-effectiveness 
results for raltegravir when using a 192 week time frame.
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